{"title":"Felicia Pagliuca.","authors":"Felicia Pagliuca","doi":"10.1016/j.xcrm.2025.102142","DOIUrl":null,"url":null,"abstract":"<p><p>Dr. Felicia Pagliuca is currently Senior Vice President, Cell and Genetic Therapy Research at Vertex Pharmaceuticals. She received a BS from Duke University and a PhD from Cambridge University where she was a Marshall Scholar. She completed her postdoctoral fellowship with Dr. Douglas Melton at the Harvard Stem Cell Institute, where she worked with Dr. Melton to discover how to generate stem cell-derived pancreatic beta cells in the lab. She co-founded Semma Therapeutics with Dr. Melton in 2014. While at Semma, she served as Vice President of Cell Biology Research and Development, where she led the development of investigational cell therapies for the treatment of type 1 diabetes. She joined Vertex Pharmaceuticals in 2019, when Semma was acquired by Vertex, and served as the company's Vice President and Disease Area Executive for type 1 diabetes for 5 years before moving into her current role.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 5","pages":"102142"},"PeriodicalIF":11.7000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102142","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Dr. Felicia Pagliuca is currently Senior Vice President, Cell and Genetic Therapy Research at Vertex Pharmaceuticals. She received a BS from Duke University and a PhD from Cambridge University where she was a Marshall Scholar. She completed her postdoctoral fellowship with Dr. Douglas Melton at the Harvard Stem Cell Institute, where she worked with Dr. Melton to discover how to generate stem cell-derived pancreatic beta cells in the lab. She co-founded Semma Therapeutics with Dr. Melton in 2014. While at Semma, she served as Vice President of Cell Biology Research and Development, where she led the development of investigational cell therapies for the treatment of type 1 diabetes. She joined Vertex Pharmaceuticals in 2019, when Semma was acquired by Vertex, and served as the company's Vice President and Disease Area Executive for type 1 diabetes for 5 years before moving into her current role.
Cell Reports MedicineBiochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
15.00
自引率
1.40%
发文量
231
审稿时长
40 days
期刊介绍：
Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine.
Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
